semaj83/ctmatch_classification huggingface dataset:
Patient description: The patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. A core biopsy revealed a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant. The tumor is HER2-positive and ER/PR negative. Axillary sampling revealed 5 positive lymph nodes. CXR was remarkable for metastatic lesions. The patient is using multivitamins and iron supplements. She does not smoke or consume alcohol. She is not sexually active and has no children. She is a candidate for tumor resection and agrees to do so prior to chemotherapy.

Clinical trial eligibility criteria: eligible ages (years): 0.0-999.0,  Breast Cancer All patients must have histologically confirmed and newly diagnosed breast cancer: node-positive stage IIA and any stage IIB, III. PET results will determine node positivity. If PET was not utilized, sonographically positive node should be confirmed cytologically by fine needle aspiration No prior hormonal, chemotherapy or radiotherapy is allowed No breast operation other than biopsy to make diagnosis is allowed Age: 18-years and older, not pregnant pre-, and postmenopausal women with good performance status (ECOG 0-1) Adequate hematopoietic function: Absolute granulocyte count ³1500/mm3, platelet ³100,000/mm3, Hemoglobin ³ 10 g/mm3 Adequate renal function: Serum creatinine £ 1.5 mg/dl Adequate hepatic function: total bilirubin: £ 1.5 mg/dl, AST/ALT: £ two times normal, Alkaline phosphatase: £ two times normal Adequate cardiac function: normal or nonspecific EKG taken within 1 mo of enrollment Adequate mental function to understand and sign the consent  Patients who received hormonal, chemotherapy or radiotherapy for breast cancer Patients who underwent surgery for breast cancer Patients with node-negative stage IIA breast cancer Patients who have history of cancer other than in situ uterine cervix cancer or nonmelanotic skin cancer
Patient description: The patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. A core biopsy revealed a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant. The tumor is HER2-positive and ER/PR negative. Axillary sampling revealed 5 positive lymph nodes. CXR was remarkable for metastatic lesions. The patient is using multivitamins and iron supplements. She does not smoke or consume alcohol. She is not sexually active and has no children. She is a candidate for tumor resection and agrees to do so prior to chemotherapy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Breast Cancer Women with histologically/cytologically confirmed locally advanced or metastatic breast cancer 2. Primary tumor or metastases are HER2-ICH3+ or FISH+ 3. Measurable or non-measurable disease 4. The patients must not have received treatment with the combination trastuzumab and vinorelbine previously 5. Expected lifetime of more than 12 weeks 6. Age ≥ 18 years 7. Performance status ≤ 2 according to World Health Organization (WHO) scale 8. The patient must be able to comply with the protocol 9. Verbal and written informed consent  Women who are pregnant or breast-feeding. A negative pregnancy test must be provided during the screening period for fertile women. Fertile women must use effective contraceptive methods 2. Clinical symptoms indicating central nervous system involvement 3. Other current or former malignant disease, with the exception of adequately treated and cured carcinoma in situ cervicis uteri and basocellular skin carcinomas 4. Left ventricular ejection fraction (LVEF) < 50% of normal range 5. Reduced bone marrow function defined by leukocyte counts < 3.0 x 109/l and neutrophil counts < 1.5 x 109/l, or thrombocyte counts ≤ 100 x 109/l 6. Reduced liver function defined by bilirubin > 3 x upper normal limit and/or ASAT/ALAT > 3 x upper normal limit and/or alkaline phosphatase > 3 x upper normal limit. 7. Reduced renal function defined by serum creatinine > 2 x upper normal limit
Patient description: The patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. A core biopsy revealed a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant. The tumor is HER2-positive and ER/PR negative. Axillary sampling revealed 5 positive lymph nodes. CXR was remarkable for metastatic lesions. The patient is using multivitamins and iron supplements. She does not smoke or consume alcohol. She is not sexually active and has no children. She is a candidate for tumor resection and agrees to do so prior to chemotherapy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-75.0,  Breast Cancer Women with Estrogen Receptor (ER), Progesterone Receptor (PR),and HER2 negative invasive breast cancer confirmed on core biopsy.(Note: HER2 negative by FISH preferred; HER2 0 or 1+ by IHC acceptable) Primary tumor size 2cm or greater by physical exam or radiographic measurements.(Note: Locally advanced T4 or inflammatory breast cancer is eligible.) Assessment of pre-treatment axillary lymph nodal status (Note: FNA biopsy if palpable or sentinel lymph node biopsy (SLNB) if not palpable preferred; clinical exam acceptable.) Absolute neutrophil count > 1500 mm3 and platelet count > 100,000 mm3 Normal myocardial left ventricular function Serum creatinine < 2.0 mg/dl Total bilirubin and AST < 3X upper limits normal  Recurrent or metastatic breast cancer findings (Note: If oncologically felt to be a second breast primary, patient eligible for this protocol) Another active cancer present Medical contraindications to chemotherapy or surgery First trimester pregnancy Breast feeding
Patient description: The patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. A core biopsy revealed a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant. The tumor is HER2-positive and ER/PR negative. Axillary sampling revealed 5 positive lymph nodes. CXR was remarkable for metastatic lesions. The patient is using multivitamins and iron supplements. She does not smoke or consume alcohol. She is not sexually active and has no children. She is a candidate for tumor resection and agrees to do so prior to chemotherapy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-65.0,  Breast Cancer Histologically confirmed breast cancer: at least three fast biopsies Primary tumor ≥2 cm acc. to clinical measurement or manifestation of an inflammatory breast cancer No systemic metastasis, by chest x-ray, sonogram of the upper abdomen and skeletal scintiscan Age ≥18 years and ≤65 years ECOG < 2/WHO 0-1 Adequate organ function defined as SGOT and bilirubin ≤ 1.5× upper limit WBC ≥ 3000 /µL Neutrophils ≥ 1000 /µL Platelets ≥ 100,000 /µL Serum creatinine < 2.0 mg/dL Unremarkable heart echo No florid hepatitis Written consent to participate in the treatment optimization protocol  Multicentricity in various quadrants (contact the study office) Known allergy to E. coli-produced medication Known allergy to medication containing cremophor (e.g., cyclosporin A) Patients receiving immunosuppressant therapy Lack of consent after informing the patient Lack of willingness to keep and disclose personal medical data as part of the study Pregnancy, nursing Secondary malignancy, excluding basalioma of the skin or carcinoma in situ of the cervix that has received curative therapy Pre-existing treatment-resistant cardiac disease, coronary heart disease, arrhythmias, cardiac insufficiency Patients with uncontrolled hypertension (diastolic >95 mmHg)
Patient description: The patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. A core biopsy revealed a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant. The tumor is HER2-positive and ER/PR negative. Axillary sampling revealed 5 positive lymph nodes. CXR was remarkable for metastatic lesions. The patient is using multivitamins and iron supplements. She does not smoke or consume alcohol. She is not sexually active and has no children. She is a candidate for tumor resection and agrees to do so prior to chemotherapy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Metastatic Breast Cancer Postmenopausal women defined as: aged >/= 50 years with amenorrhea for at least 12 months or aged < 50 years with 6 months of spontaneous amenorrhea and follicle stimulating hormone (FSH) level within postmenopausal range (> 40 mIU/ml) or having undergone bilateral oophorectomy Histologically or cytologically confirmed breast cancer Metastatic breast cancer (Stage IV according to UICC Union Internationale Contre Cancer Version 6) Progesterone receptor-positive tumors Patients must be considered candidates for endocrine therapy (no other therapies for breast cancer are required) Disease progression after first-line endocrine therapy for advanced breast cancer (i.e. with tumor remission or stabilization lasting at least 3 months under endocrine therapy) At least one measurable or non-measurable tumor lesion (according to criteria) WHO Performance status 1  Presence of any of the following conditions life-threatening metastatic visceral disease (extensive hepatic involvement) any metastases to the central nervous system (CNS) pulmonary lymphangitic metastases involving more than 50% of the lung More than one prior endocrine treatment for advanced breast cancer Previous combination of endocrine treatment with any other type of treatment (except chemotherapy), or previous sequential endocrine treatments (if there was disease progression between treatments) are not permitted in this trial Patients with breast cancer HER-2 positive or with unknown HER-2 status are not eligible Malignancies or history of prior malignancy other than carcinoma in situ of the cervix or uterus, or basal and squamous cell carcinoma of the skin Intake of CYP3A4 inhibitors less than 2 weeks before start of study treatment A marked baseline prolongation of QT/QTc interval (e.g., repeated demonstration of a QTc interval >450 milliseconds (ms)
Patient description: The patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. A core biopsy revealed a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant. The tumor is HER2-positive and ER/PR negative. Axillary sampling revealed 5 positive lymph nodes. CXR was remarkable for metastatic lesions. The patient is using multivitamins and iron supplements. She does not smoke or consume alcohol. She is not sexually active and has no children. She is a candidate for tumor resection and agrees to do so prior to chemotherapy.

Clinical trial eligibility criteria: eligible ages (years): 40.0-999.0,  Breast Cancer Patients with biopsy-proven DCIS, mammographic and CE-MRI evidence of DCIS measuring great then equal to 4cm, and a desire to receive breast conserving therapy, will be considered for participation in this study Patient history, physical examination findings, and demographics (sex, age, height, weight, bra size, etc.) will be performed and documented. for Initial Registration (all patients cohorts): All cohorts Signed informed consent and HIPAA documents Female sex Age great then equal to 40 years Localized ductal carcinoma in situ Clinically and/or histologically negative axillary lymph nodes No imaging or clinical findings suggestive of invasive carcinoma. Cohort 1 (Immediate IORT group) Localized DCIS measuring less then equal to 4 cm on preoperative imaging Cohort 2 (Delayed IORT group)  Male sex Age less than 40 DCIS associated with any evidence of microinvasion or invasive carcinoma on pre-operative imaging or core biopsy of the breast or axillary nodes DCIS that is multicentric in the ipsilateral breast. Multicentricity will be defined at 2 or more lesions separated by more than 3 cm in the same breast Non-epithelial breast malignancies such as sarcoma or lymphoma DCIS associated with diffuse suspicious or indeterminate microcalcifications Pregnancy or lactation Collagen vascular diseases, including Systemic lupus erythematosus, Systemic sclerosis (scleroderma), CREST Syndrome (calcinosis, Raynaud phenomenon, esophageal dysfunction, sclerodactyly, telangiectasia, and the presence of anticentromere antibodies), polymyositis, dermatomyositis with a CPK level above normal or with an active skin rash, inclusion-body myositis, or amyloidosis Serious psychiatric or addictive disorders
Patient description: The patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. A core biopsy revealed a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant. The tumor is HER2-positive and ER/PR negative. Axillary sampling revealed 5 positive lymph nodes. CXR was remarkable for metastatic lesions. The patient is using multivitamins and iron supplements. She does not smoke or consume alcohol. She is not sexually active and has no children. She is a candidate for tumor resection and agrees to do so prior to chemotherapy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-120.0,  Breast Cancer Histologically or cytologically confirmed adenocarcinoma of the breast Metastatic disease Measurable disease, defined as ≥ 1 unidimensionally measurable lesion ≥ 20 mm by conventional techniques (i.e., MRI or CT scan of chest, abdomen and pelvis) or ≥ 10 mm by spiral CT scan Non-measurable disease allowed, defined as all other lesions (or sites of disease), including small lesions (longest diameter < 20 mm by conventional techniques or < 10 mm by spiral CT scan) Must have objective evidence of progression within the past 3 months No human epidermal growth factor receptor 2 (HER2)/neu overexpression, defined as gene amplification by fluorescence in situ hybridization or 3+ overexpression by immunohistochemistry, or unknown HER2/neu status No active brain metastases Patients with neurological symptoms must undergo a contrast CT scan or MRI of the brain to active brain metastasis Patients with treated brain metastases allowed provided they have no evidence of disease and have been off definitive therapy (including steroids) for the past 3 months Hormone receptor status
Patient description: The patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. A core biopsy revealed a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant. The tumor is HER2-positive and ER/PR negative. Axillary sampling revealed 5 positive lymph nodes. CXR was remarkable for metastatic lesions. The patient is using multivitamins and iron supplements. She does not smoke or consume alcohol. She is not sexually active and has no children. She is a candidate for tumor resection and agrees to do so prior to chemotherapy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Breast Cancer All tumors must be ER-, PR and HER2-negative Clinical stage T2 or T3, N0-3, M0. Subjects with inflammatory breast cancer are not eligible For subjects with clinically negative axilla, a sentinel lymph node biopsy will be performed either up front or after preoperative therapy at the discretion of the subject's physicians; for subjects with a clinically positive axilla, a needle aspiration or core biopsy will be performed to confirm the presence of metastatic disease in the lymph nodes years of age or older Performance status (PS) of 0 or 1 Use of an effective means of contraception in subjects of child-bearing potential Normal organ function as described in the protocol  Any prior cytotoxic chemotherapy or radiation for the current breast cancer HER2-negative ipsilateral breast recurrence, unless prior treatment consisted of excision alone for ductal carcinoma in situ (DCIS)or breast-conserving treatment and hormonal therapy for DCIS or invasive cancer Life expectancy of less than 12 weeks Current, recent, or planned participation in an experimental durg study other than a Genentech-sponsored bevacizumab cancer study Renal dysfunction for which exposure to cisplatin would require dose modifications Steroid dependent asthma Peripheral neuropathy of any etiology that exceeds grade 1 Uncontrolled diabetes History of malignancy treated without curative intent Any other pre-existing medical condition that would represent toxicity in excess of grade 1
Patient description: The patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. A core biopsy revealed a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant. The tumor is HER2-positive and ER/PR negative. Axillary sampling revealed 5 positive lymph nodes. CXR was remarkable for metastatic lesions. The patient is using multivitamins and iron supplements. She does not smoke or consume alcohol. She is not sexually active and has no children. She is a candidate for tumor resection and agrees to do so prior to chemotherapy.

Clinical trial eligibility criteria: eligible ages (years): 40.0-999.0,  Breast Cancer Patient with unifocal histologically proven breast cancer, with or without calcifications in mammogram DCIS (Ductal carcinoma in situ) (Tis, Stage 0) Non-lobular infiltrating carcinoma, maximum of 2 cm in diameter. (T1, Stage I) The patient was operated on and the tumor was excised with lumpectomy The tumor is reported with negative margins >3 mm, as per our hospital protocol For invasive carcinoma, axillary lymph nodes are negative by sentinel lymph node (SLN) mapping and biopsy or by formal axillary lymph node dissection The patient is over 40 years old with life expectancy of at least 5 years Karnofsky status must be at least 70. See appendix I Pre and post-menopausal women are eligible for entry  No concurrent or neoadjuvant chemotherapy is allowed. Patient is permitted to be treated with chemotherapy or hormone therapy only after completion of the radiation treatment Patients with diffuse calcifications, multifocal or multicentric disease, lymph-vascular invasion are excluded Patients cannot participate if there is extensive LCIS (Lobular carcinoma in situ) in specimen or extensive DCIS Patients are excluded if systemic disease is present or the patient has been irradiated to the ipsilateral breast or the chest wall Patients who are carriers of BRCA 1/2 mutations or at high risk for hereditary breast cancer due to strong family history (more than one pre-menopausal family member with breast cancer or any ovarian cancer) are excluded because of the increased potential for in-breast recurrence elsewhere in the breast in the absence of whole breast radiotherapy Patients with scleroderma, or systemic or discoid lupus are excluded due to the potential for significant radiotherapy associated toxicity Pregnant woman cannot participate in the study Patients who have serious medical problems which would limit survival to <5 years or a psychiatric condition which would prevent informed consent cannot participate Patients who are unable to lie on their back and raise their arms above their heads in the treatment planning position for radiotherapy are excluded Patients that have mammographically occult disease are excluded
Patient description: The patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. A core biopsy revealed a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant. The tumor is HER2-positive and ER/PR negative. Axillary sampling revealed 5 positive lymph nodes. CXR was remarkable for metastatic lesions. The patient is using multivitamins and iron supplements. She does not smoke or consume alcohol. She is not sexually active and has no children. She is a candidate for tumor resection and agrees to do so prior to chemotherapy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-120.0,  Breast Cancer Long-term Effects Secondary to Cancer Therapy in Adults Skin Reactions Secondary to Radiation Therapy Women who have chosen to undergo breast conservation therapy, including lumpectomy and breast irradiation, at the University of Pennsylvania for any invasive mammary carcinoma or intraductal breast cancer Stage I-II invasive or intraductal breast cancer Unifocal tumor ≤ 3.0 cm in size Patients with microscopic multifocality are eligible provided total pathologic tumor size is ≤ 3 cm No proven multicentric carcinoma in more than 1 quadrant or separated by 4 or more centimeters Pre or post-biopsy ipsilateral* breast MRI negative for multicentric disease (i.e., areas of cancer that cannot be removed in a single excision specimen) or other suspicious findings NOTE: *Patients with synchronous bilateral breast cancers who will be treated with radiotherapy to each breast are eligible, provided such treatment can be performed in a manner that avoids overlap between treatment fields. Both sides may be treated with partial breast irradiation (PBI) if the pathologic are met for both tumors, or only one side may be treated with PBI if the are met for only one tumor Negative margins of excision (≥ 2 mm) OR no tumor seen in a re-excision specimen No extensive intraductal component present Negative sentinel lymph node (SLN) or axillary lymph node dissection OR fewer than 4 positive nodes on adequate axillary lymph node dissection (i.e., 10 or more lymph nodes removed)
Patient description: The patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. A core biopsy revealed a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant. The tumor is HER2-positive and ER/PR negative. Axillary sampling revealed 5 positive lymph nodes. CXR was remarkable for metastatic lesions. The patient is using multivitamins and iron supplements. She does not smoke or consume alcohol. She is not sexually active and has no children. She is a candidate for tumor resection and agrees to do so prior to chemotherapy.

Clinical trial eligibility criteria: eligible ages (years): 21.0-999.0,  Breast Cancer Histologically confirmed primary invasive breast carcinoma Stage I-IIA disease (T1, N0, M0 or T2, N0, M0) Pathologically determined single, discrete, and well-defined primary tumor ≤ 5 cm in diameter Pathologically negative surgical margins No multicentric disease and/or diffuse malignant appearing microcalcifications Micro-calcifications must be focal Specimen radiograph is required after lumpectomy for tumors associated with malignant appearing calcifications to assure removal of all malignant appearing calcifications Specimen radiograph is optional if the tumor appears as a discrete mass on mammogram No axillary lymph node involvement No evidence of metastatic breast cancer